Clinical trials: Dermatomyositis, Adult Type
Myositis, Active Idiopathic Inflammatory Myopathy
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
The main purpose of this study is to measure the long-term safety and tolerability of efgartigimod PH20 SC in adult participants with Idiopathic Inflammatory Myopathy (IIM) who previously participated in ARGX-113-2007.
- Conditions
- Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis
- Trial name
- ALKIVIA+ (NCT05979441)
- Testing
- Efgartigimod PH20 SC
- Where
- 92 sites in United States, Argentina and 27 more
- Volunteers
- 240 people
- Sponsor
- argenx
Dermatomyositis, Polymyositis
Dermatomyositis and Polymyositis Registry
By creating a registry, physicians will have the opportunity to understand the clinical outcomes of Myositis patients treated with Acthar.
- Trial name
- ADAPT (NCT01637064)
- Testing
- Acthar
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- Phoenix Neurological Associates, LTD
Glucocorticoid-Associated Osteopenia and Osteoporosis
Alendronate Osteoporosis Study
This trial will test the hypothesis that among 20 children and adolescents from Children's Hospital, Boston with Crohn's disease, ulcerative colitis, systemic-onset juvenile rheumatoid arthritis, juvenile dermatomyositis…
- Trial name
- NCT00277251
- Testing
- Alendronate
- Volunteers
- 20 people
- Sponsor
- Boston Children's Hospital
Rheumatic Diseases, Arthritis
Pain-Sleep in Rheumatic Disease
Overall, our understanding of how pain and sleep are experienced and how they can be treated in teenagers with rheumatic diseases is limited.
- Conditions
- Rheumatic Diseases, Arthritis, Lupus, Lupus Arthritis, Systemic Lupus Erythematosus
- Trial name
- NCT07775612
- Testing
- Better Nights, Better Days for Youth
- Volunteers
- 43 people
- Sponsor
- The Hospital for Sick Children
Polymyositis, Dermatomyositis
Study of the Prevalence of Polymyositis and Dermatomyositis in Normandy
Polymyositis and dermatomyositis are characterized by the association to a myopathic syndrome, inflammatory infiltrates in the skeletal muscle.
- Trial name
- EPIDEMYOSITIS (NCT02880527)
- Testing
- Patients with polymyositis / dermatomyositis
- Where
- France
- Volunteers
- 187 people
- Sponsor
- University Hospital, Rouen
Calcinosis
Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis
Dermatomyositis is an inflammatory muscle disorder that is often associated with many skin findings. One of the skin findings seen in up to 50% of individuals with juvenile dermatomyositis, an early onset form of this condition…
- Trial name
- NCT01572844
- Testing
- Fractionated Carbon Dioxide (FCO2) Laser, Sodium thiosulfate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Alison Ehrlich
Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Systemic Sclerosis Pulmonary
Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases
The RMD-mILDer trial is a home monitoring strategy trial aiming to improve management of interstitial lung disease related to rheumatic diseases applying eHealth technology.
- Conditions
- Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Systemic Sclerosis Pulmonary, Dermatomyositis, Rheumatoid Arthritis
- Trial name
- RMD-mILDer (NCT06732674)
- Testing
- A home monitoring strategy with event driven management
- Where
- Norway
- Volunteers
- 218 people
- Sponsor
- Oslo University Hospital
Dermatomyositis, Polymyositis
Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis
This study will examine whether infliximab (Remicade ) is safe and effective for the treatment of dermatomyositis and polymyositis.
- Trial name
- NCT00033891
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Lung; Disease, Interstitial, With Fibrosis, Dermatomyositis
Basiliximab Treating Interstitial Pneumonia of CADM
This is a 52-week, randomized, open and routine treatment controlled study. This study will assess the safety and efficacy of basiliximab as an add-on treatment for interstitial pneumonia in clinical amyopathic dermatomyositis…
- Trial name
- NCT03192657
- Testing
- Basiliximab, Calcineurin Inhibitors, Steroids
- Where
- China
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
Juvenile Dermatomyositis
Incidence and Prevalence of Juvenile Dermatomyositis
This is a descriptive, retrospective, multi-center, cross-sectional and observational epidemiological study of incidence and prevalence of juvenile dermatomyositis in Alsace from 2000 to 2015.
- Trial name
- NCT03432455
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Strasbourg, France
DERMATOMYOSITIS OR POLYMYOSITIS
A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis
The primary objective of the study is to evaluate the safety and tolerability of multiple IV doses of MEDI-545 in adult patients with myositis.
- Trial name
- NCT00533091
- Testing
- MEDI-545
- Where
- 14 sites in United States
- Volunteers
- 51 people
- Sponsor
- MedImmune LLC
Dermatomyositis
Exercise Capacity of Patients with Dermatomyosis
Dermatomyositis (DM) patients experience muscle weakness and low aerobic capacities, which are associated with poor health status and increased mortality. The origin of this muscle impairment remains unknown.
- Trial name
- MIDE (NCT03293615)
- Testing
- exploration
- Where
- France
- Volunteers
- 3 people
- Sponsor
- University Hospital, Strasbourg, France
Refractory Autoimmune Diseases
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory…
- Trial name
- NCT07115745
- Testing
- BMS-986515, Fludarabine, Cyclophosphamide
- Where
- 28 sites in United States, Australia and 8 more
- Volunteers
- 125 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Inflammation In Skeletal Muscle
Natural History of Inflammatory Muscle Diseases
Objective: To collect information and biospecimens (such as blood, muscle, and skin samples) that will be used to research causes and treatments of inflammatory muscle diseases.
- Trial name
- NCT05738824
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Dermatomyositis
A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis
The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered GLPG3667 once daily for 24 weeks in adult participants with dermatomyositis…
- Trial name
- GALARISSO (NCT05695950)
- Testing
- GLPG3667
- Where
- 54 sites in United States, Argentina and 13 more
- Volunteers
- 40 people
- Sponsor
- Lakefront Biotherapeutics NV
Dermatomyositis
Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of dermatomyositis.
- Trial name
- DETERMINE (NCT03813160)
- Testing
- Lenabasum 20 mg, Lenabasum 5 mg
- Where
- 54 sites in United States, Bulgaria and 11 more
- Volunteers
- 176 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Dermatomyositis
3T Therapy in the Treatment of MDA5-positive Dermatomyositis
The goal of this clinical trial is to learn if a combination of tacrolimus, tafocitinib and thalidomide (3T therapy) works to treat severe MDA5 positive dermatomyositis in adults.
- Trial name
- NCT06438679
- Testing
- Tofacitinib 5 MG
- Where
- China
- Volunteers
- 133 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Systemic Sclerosis, Systemic Lupus Erythematosus
Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders
OBJECTIVES: I. Determine the safety and long term complications of total body irradiation in combination with cyclophosphamide, anti-thymocyte globulin, and autologous CD34-selected peripheral blood stem cell (PBSC)…
- Conditions
- Systemic Sclerosis, Systemic Lupus Erythematosus, Dermatomyositis, Juvenile Rheumatoid Arthritis
- Trial name
- NCT00010335
- Testing
- Stem Cell Transplantation, CD34 selection
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Fred Hutchinson Cancer Center
Dermatomyositis
Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis
Juvenile dermatomyositis (JDMS) is one of the most serious of the childhood rheumatic diseases. The theory behind this trial is that early introduction of etanercept or methotrexate will prove to be effective in the treatment of…
- Trial name
- NCT00035958
- Testing
- Prednisone, Methotrexate, Etanercept
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati